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ABSTRACT Structures in four different crystal forms of
[Leul'zervamicin (zervamicin Z-L, Ac-Leu-Ile-Gln-Iva-11e5-
Thr-Aib-Leu-Aib-Hypl0-Gln-Aib-Hyp-Aib-Prol5-Phol, where
Iva is isovaline, Aib is a-amino isobutyric acid, Hyp is 4-hy-
droxyproline, and Phol is phenylalaninol), a membrane channel-
forming polypeptide from Emericellopsis salmosynnemata, have
been determined by x-ray diffraction. The helical structure is
amphiphilic with all the polar moieties on the convex side of the
bent helix. Helices are bent at Hyp'0 from =30° to -450 in the
different crystal forms. In all crystal forms, the peptide helices
aggregate in a similar fashion to form water channels that are
interrupted by hydrogen bonds between NeH(Glnll) and
06(Hyp"') of adjacent helices. The Gin" side chain is folded in
an unusual fashion in order to close the channel. Space is
available for an extended conformation for Gin", in which case
the channel would be open, suggesting a gating mechanism for
cation transport. Structural details are presented for one crystal
form derived from methanol/water solution: CwH14N,8On
1OH20, space group P21, a = 23.068(6) A, b = 9.162(3) A, c =
26.727(9) A, ,B = 108.69(2)0 (standard deviation of last digit is
given in parentheses); overall agreement factor R = 10.1% for
5322 observed reflections [IFo1 > 3a(F)]; resolution, 0.93 A.
Several acyclic, a-aminoisobutyric acid (Aib)-containing
polypeptides of fungal origin (Fig. 1) form voltage-gated
channels in phospholipid bilayer membranes (1-6). The best
studied members of this class are alamethicins, 20-residue
peptides for which a crystal structure has been reported at
1.5-A resolution (3). Several models for alamethicin ion
channels have been proposed (3-6), based on the helical
conformation observed in crystals. The molecular packing in
alamethicin crystals, however, did not directly provide a
model for a membrane-phase channel aggregate (3). The
zervamicins are a related class of peptides isolated from
cultures of Emericellopsis salmosynnemata (7). These pep-
tides are shorter (16 residues) than alamethicin and contain
several polar residues (Thr, Gln, Hyp) distributed evenly
throughout the sequence (8). A preliminary report suggests
that zervamicins exhibit lower pore-forming ability and en-
hanced antibacterial properties compared with alamethicin
(8). More recently, the zervamicins have been shown to form
voltage-dependent multilevel ion channels in bilayer mem-
branes (ref. 9; M. S. P. Sansom, personal communication).
Although the conductive activity is qualitatively similar to
that of alamethicin, the kinetics of switching between states
is appreciably faster for zervamicins. The major polypeptide
components of zervamicin (IIA and IIB) contain a Trp
residue at position 1. During HPLC fractionation, a minor
Alamethicin I (11)
Antiamoebin I (II)
Zervamicin ILA (IIB)
Ac-Aib-Pro-Aib-Ala-Aib5-Ala(Aib)-Gln-Aib-Val-
Aibl O-Gly-Leu-Aib-Pro-Vall 5-Aib-Aib-Glu-Gln-Phol20
Ac-Phe-Aib-Aib-Aib-D-Iva5-Gly-Leu-Aib-Aib-Hyp10-
Gln-D-Iva-Hyp(Pro)-Aib-Pro 1 5-Phol
Ac-Trp-Ile-Gln-Aib(Iva)-Ile5-Thr-Aib-Leu-Aib-
Hypl O-Gln-Aib-Hyp-Aib-Prol 5-Phol
Zervamicin Z-L Ac-Leu-lle-Gln-lva-Ile5-Thr-Aib-Leu-Aib-
HypI0-Gln-Aib-Hyp-Aib-Pro 5-Phol
FIG. 1. Sequences of some Aib-containing antibiotics that trans-
port ions across membranes. Phol, phenylalaninol; Iva, isovaline
(a-ethylalanine); Hyp, 4-hydroxyproline.
component containing Leu at position 1, [Leul]zervamicin
(zervamicin Z-L), has been isolated. The component has
been crystallized and the structure determined in four differ-
ent crystal forms to resolutions as high as 0.93 A and R =
10.1% (Table 1). In each of the four different crystal forms,
space groups P21 and P212121, the peptide molecules asso-
ciate to form similar discontinuous water channels, which
appear to give further insights into the nature of an ion
channel, a possible gating mechanism, and the dynamics of a
bent helix molecule.
EXPERIMENTAL PROCEDURES
[Leu']Zervamicin was isolated from a heterogeneous zer-
vamicin mixture by HPLC on a reverse-phase C18 column, as
described (10). Crystals were grown by slow evaporation of
methanol/water solution or by vapor diffusion of water into
ethylene glycol/ethanol solutions containing about 3 mg of
peptide in 0.4 ml of solvent. X-ray diffraction data were
measured with a four-circle automated diffractometer with
CuK,,a radiation on crystals under the conditions listed in
Table 1 for a best set of data. Lowering the temperature for
some of the crystal forms resulted in shattering the crystal.
Rapid scan speeds, 7-15°/min, were used in order to collect
most ofthe data before significant deterioration ofthe crystal.
The structures were solved by a vector-search procedure (11)
contained in the SHELX84 package of programs (MicroVAX
version of the SHELXTL system of programs; Siemens Instru-
ments, Madison, WI). The search model was based on the
backbone atoms ofthe known structure ofa 16-residue apolar
analog of zervamicin (12) and was followed by a partial-
structure procedure (13) by which the atoms in the side chains
were located. The detailed structure only of crystal A will be
reported here. Full-matrix anisotropic least-squares refine-
Abbreviations: Aib, a-aminoisobutyric acid (a-methylalanine); Hyp,
4-hydroxyproline; Iva, isovaline (a-ethylalanine); Phol, phenylalan-
inol.
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Table 1. Crystal parameters for Ac-Leu-Ile-Gln-Iva-Ile-Thr-Aib-Leu-Aib-Hyp-Gln-Aib-Hyp-Aib-
Pro-Phol, C85H14ON18022'xH2O
Parameter Crystal A*t Crystal Bt Crystal C Crystal D
Space group P21 P21 P212121 P212121
Cell dimensions
a, A 23.068(6) 21.857(4) 10.337(2) 10.160(3)
b, A 9.162(3) 9.381(3) 28.389(7) 28.252(9)
c, A 26.727(9) 26.744(6) 39.864(11) 40.338(9)
,(, degrees 108.69(2) 105.22(2) 90 90
Growth solvent CH30H/H20 CH30H/H20 HOCH2CH20H :
No. of reflections
[IF01 > 3o(F)] 5322 2939 4239 2251
Crystal condition -450C, dry 20'C, dry 20'C, in capillary 20'C, in capillary
Volume per
asymmetric unit, A3 2676 2638 2924 2895
*R = TIIFoI - IFcII/XIFOI for all data with 1F01 > 3a(F) = 10.1%; resolution, 0.93 A. Estimated SDs for
backbone: -0.023 A (bonds); -1.3° (angles). Estimated SDs for side chains: -0.03 A (bonds); -1.7°
(angles).
tCrystals A and B were present in the same crystallizing vial.
tCrystal D was obtained by soaking crystal C in aqueous KCI (no K+ in crystal D); approximate
coordinates for the peptide are known, but least-squares refinement was not completed.
ment was performed on the C, N, and 0 atoms in the peptide,
after which H atoms were placed in idealized positions with
C-H distances of 0.96 A and allowed to ride with the C or N
atoms to which each was bonded for the final cycles of
refinement. The thermal factors for the H atoms were fixed
at UiO = 0.125. Water molecules for a total of 11 sites (one
pair of sites is mutually exclusive) were located in a series of
difference maps and added stepwise to the refinement. The
phenyl group in the Phol residue was constrained to be a
regular hexagon with C-C distances of 1.395 A, although the
position and orientation of the hexagon and the isotropic
thermal values for each atom in the hexagon were subjected
to least-squares refinement. Finally, the amide moiety in the
Gln3 side chain, particularly the Ne(3) atom (in all the crystal
forms) was particularly mobile; therefore the bond lengths
and bond angles in the -C(O)NH2 moiety were constrained to
reasonable values while the orientation of the amide group
and the isotropic thermal factors associated with the C8(3),
O(3), and N8(3) atoms were allowed to vary in the least-
squares process. With the above constraints, and not quite a
full sphere of data to a resolution of 0.93 A due to the onset
of crystal deterioration, the final R factor is 10.1% for 5322
data observed with IFOI > 3o-(F). Bond lengths and bond
angles (estimated SD, approximately 0.02 A for bonds and
1.2° for angles) do not show significant or systematic differ-
ences from expected values.t
RESULTS
The Peptide Helix. Both alamethicin and zervamicin have
a high proportion of Aib residues, which are strong helix
formers (14-16). Zervamicin has polar moieties in residues 3,
6, 10, 11, 13, and 16. As expected for a helical structure with
polar residues spaced at each third or fourth position (17, 18),
all of these polar moieties are on one side of the zervamicin
helix (Fig. 2), thus giving the helix an amphiphilic character.
Although Gln" would appear to break the rule, the torsions
about the Ca-CO and CO-C8 bonds in Gln11 are -51° and
-55°, respectively, which fold the polar -C(O)NH2 group
back from the nonpolar face to the polar face ofthe helix. The
unusual conformation and the probable mobility of the Gln"1
tSupplementary material consisting of atomic coordinates for C, N,
and 0 atoms, bond lengths and angles, anisotropic thermal factors,
and coordinates for hydrogen atoms has been deposited with the
Cambridge Structural Data Base, University Chemical Laboratory,
Lensfield Road, Cambridge CB2 IEW, U.K. Lists of observed and
calculated structure factors are available from I.L.K. and J.L.F.-A.
side chain strongly suggest the location of the gating mech-
anism during ion transport (see below). Additionally, the
polar face is enhanced by the exposed backbone carbonyl
oxygens in residues 6, 7, and 10, which do not participate in
intrahelical hydrogen bonds (Table 2) due to the presence of
Hyp'0 and Hyp13. These carbonyls are available for hydrogen
bonding to the neighboring water molecules or another
peptide molecule or for making transient ligands with cations
that are being transported.
Despite the presence of two Hyp residues and one Pro
residue, the backbone is entirely helical. Torsional angles are
listed in Table 3. An a-helix is formed from the amino
terminus through the ninth residue. A 8-ribbon containing
Hyp1o, Hyp13, and Pro"5 is twisted into a helix that extends
to the carboxyl terminus. The helix is bent at Hyp10, giving
the peptide an overall banana shape. It is interesting that the
GLN LEU
d - 1
2
IVA
THR ILE
AIB o 7
LEU 2
11P AIB a
0J12 z~
AIB~~~~~I
1 PHOL
16
FIG. 2. Conformation of [Leul]zervamicin drawn with the coor-
dinates obtained from crystal A. The Cc atoms are labeled 1-16. The
side chain in Gln"1 (filled circles) is not extended to the hydrophobic
face but folded backward to the polar face of the helix.
5308 Biochemistry: Karle et al.
Proc. Natl. Acad. Sci. USA 88 (1991) 5309
Table 2. Hydrogen bonds
Peptide helix
N .0* or H O.. 0,* C=
Type Donor Acceptor O ... O, A A angl
Head-to-tail N(1) 0(15)t 2.93 2.04
Intramolecular
5 1
Intramolecular
5 1
Intermolecular
13-Ribbon
Intermolecular
(3-Ribbon
N(2)
N(3)
N(4)
N(5)
N(6)
OY(6)
N(7)
N(8)
N(9)
06(10)t
NE(11)§
NE(11)§
N(11)
N(12)
08(13)
N(14)
N(16)
0(l6)t
0(3)
0(0)
0(1)
0(2)
0(2)
0(3)
0(4)
0(5)
0(7)
0(6)
0o(10)
0(8)
0(9)
0E(13)¶
0(11)
0(13)
2.96
3.07
2.85
3.15
3.25
2.79
2.88
3.36
2.98
2.75
3.09
2.91
2.88
3.15
2.67
3.01
2.82
2.07
2.32
2.01
2.26
2.40
1.97
2.03
2.60
2.26
1.91
2.22
2.06
2.01
2.26
1.85
2.12
1.99
le, degrees
Water structure
N * *O or
Donor Acceptor O ...O** A
122 W(1)
140 W(1)
W(2)
167 W(2)
158 W(3)
146 W(3)
W(4A)
155 W(4B)
131 NE(3)§
165 W(5)
W(5)
W(6)
W(6)t
138 0(16)
124 W(7)
W(8)
129 W(8)
129 W(9)
W(9)
W(10)
O'Y(6)§
0(10)
0(3)f
W(1)
0(13)
W(2)
W(3)
W(3)
W(4B)
W(4A)
W(6)
0(14)
0(3)
W(6)
W(5)
0(11)
W(g)t
0(12)11
W(8)
0(15)
*The H atoms were placed in idealized positions with the N-H distance equal to 0.96 A.
tSymmetry equivalents 1 + x, y, 1 + z to coordinates listed in supplementary material (see footnote at end of Experimental Procedures).
tSymmetry equivalents 2 - x, -1/2 + y, 1 - z.
§Symmetry equivalents 2 - x, 1/2 + y, 1 - z.$Symmetry equivalents x, 1 + y, z.
11 Symmetry equivalents x, -1 + y, z.
conformation of the backbone of a completely apolar syn-
thetic analog of [Trpl]zervamicin (12) is almost identical to
that of the backbone in the natural [Leul]zervamicin. The
configuration of the Iva residue at position 4 is R, confirming
an earlier stereochemical assignment (8).
Channel Formation. The peptide molecules in all four
polymorphs have very similar helical conformations, intra-
molecular hydrogen bonds, head-to-tail hydrogen bonds, and
interpeptide hydrogen bonds. The differences in conforma-
tion are manifested mainly by the bend of the helix, 360 for A,
300 for B, and 450 for C (structure D is not sufficiently well
refined at this time for us to make a measurement). In all the
crystals, the polar faces associate in a common antiparallel
fashion. Fig. 3 illustrates this association with a superposition
of the envelopes of the structures, showing the peptide
molecules A, B, and C. In the middle, the molecules in each
Table 3. Torsion angles* (degrees)
Residue v Kw X1 xI3 xX4
Leul -51t -45 -173 175 73, -169
Ile2 -63 -45 -178 164, -68 168
Gln3 -69 -40 -172 -67 85 15, - 139t
Iva4 -57 -54 -177 57
Ile5 -74 -35 176 172, -66 180
Thr6 -59 -44 -176 -64, 179§
Aib7 -59 -37 -171
Leu8 -91 -24 -171 -74 -75, 165
Aib9 -55 -39 -179
Hyp'o -63 -16 -177 -24 36 -35 19
Gln"i -89 -9 179 -51 -54 -44, 13511
Aib12 -51 -37 -177
Hyp13 -77 -6 -168 -21 34 -33 20**
Aib14 -53 -44 -178
PrO'5 -80 -13 -170 -10 24 -29 22tt
Phol16 -115 +7214 -69 -75, 101
The torsion angles for rotation about the bonds of the peptide backbone (4, 4, and w) and about bonds of the amino acid
side chains (X") are described in ref. 19.
*Estimated SDs, -1.5°.
tC'(0),N(1),CG(1),C'(1).fCP(3),CV(3),C8(3),0F(3), +150; CP(3),CV(3),C8(3),NE(3), -139O.
§N(6),C'(6),CP(6) ,O'Y(6) , - 64°; N(6) ,Cc1(6),CP(6) , C'Y(6) , 179°.
¶C8(10),N(10),Ca(10),C0(10), 30; Ca(10),C,(10),CV(10),O"(10), -81°.
IICN(1),CaY(1),C (11),O((11), 0440; CH(1),C.(1),C8(11), N (11) 135
**C8(13),N(13),Cc'(13),CP(13), 1°; C11(13),CP(13),CY(13),081(13), - 830.
tfC"(15),N(15)Cc'(15)C,(15), -8.
ttN(16) ,Ca(16),C(16)(CH20H),0(16)(CH20H) .
2.82
3.00
2.91
2.82
3.21
2.82
2.50
2.89
3.08
2.98
3.08
2.90
2.73
2.67
2.48
3.00
2.67
2.94
3.13
3.15
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FIG. 3. Schematic diagram showing a superposition of the enve-
lopes of [Leul]zervamicin helices in crystal A (solid line), crystal B
(dotted line), and crystal C (dashed line). The polar face ofthe helices
associates in an antiparallel fashion and forms a discontinuous water
channel that contains a different number of water molecules in each
crystal form. The channel is closed in the middle by interpeptide
hydrogen bonds involving backbone carbonyls 0(6) and 0(7) and
side chain moieties O8(Hyp'0) and NI(Gln11). The size of the mouth
of the channel is determined by the movement of O(Phol16) and
NS(Gln3) in adjacent peptide molecules.
crystal are held together with interpeptide hydrogen bonds
O(Thr6) . . NS(Glnll), NI(Glnll) . .. 08(Hypl°), and
08(Hypl°) ... O(Aib7). The banana-shaped molecules spread
apart from each other at either end by differing amounts,
related to the bend in each helix. The resulting cavities are
filled with varying amounts of water depending upon the size
of the cavity. For crystal A there are eight water sites (one
disordered) at each end. These are shown in detail in Fig. 4,
along with the hydrogen bonding between water molecules
and between peptide and water molecules.
The mouth of the water cavity is constricted or expanded
depending upon the bend in the helix. The O(Phol16) .--
NS(Gln3) separation is 3.7 A in crystal B, 6.8 A in crystal A,
and >8 A in crystal C. Despite the flexibility of the peptide,
atom O(Phol'6) is relatively rigid since it participates in head-
to-tail hydrogen bonding. The -C(O)NH2 end of Gln3, how-
ever, is quite mobile and N6(3) makes hydrogen bonds mainly
to disordered or transient water sites. The carbonyl 0(3)
makes an intrahelical hydrogen bond to the backbone N(3)
moiety of the same residue in crystal A but not in crystal B.
Gating. A continuous water channel is not formed between
the polar surfaces of adjacent peptide molecules. A view of
the middle segments of adjacent molecules, where interpep-
tide hydrogen bonding takes place and closes the channel, is
shown in Fig. 5. The view is perpendicular to that in Figs. 3
and 4 and is directed into the helices. Three molecules appear
to define the closed channel. The side chain of Gln11 is not
FIG. 4. Water molecules (e) in crystal A of [Leul]zervamicin.
The two peptide molecules are related by a twofold screw axis. The
atoms in the side chain of Gln'1 are marked with stripes. Hydrogen
bonds are indicated by dashed lines.
extended as Gln7 of alamethicin (3) but is folded backward to
form a hydrogen bond with 08(Hyp'0). The Hyp residue is
quite rigid. It is conceivable that under the application of a
potential, the Gln11 side chain can open the channel by
FIG. 5. A possible gating mechanism by Gln'1 and Thr6 in
channels formed by [Leul]zervamicin. The view of the closed
channel is perpendicular to the orientation in Figs. 3 and 4. Only the
middle residues of three adjacent peptide molecules are shown. The
water molecule closest to the closed portion of the channel is W(1)
(checkered). The carbonyl oxygen in Aib7 and the hydroxyl in Hyp10
(striped) are relatively rigid moieties and may define a boundary of
a hypothetical open channel.
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rotating into the adjacent space at the right (Fig. 5). If a
column of water is pushed through the channel in a single tile
by a cation (20), it may also be possible that the side chain in
Thr6 can rotate about the Ca-0C bond to further enlarge the
channel. As shown in Fig. 4, there are many carbonyl,
hydroxyl, and amino moieties along the channel to provide
ligands for a cation that is being transported.
Nonpolar Face of Helix. Helical peptides forming a channel
across a membrane would have their nonpolar side facing the
membrane. The molecular recognition and aggregation of
apolar helical peptides are not particularly selective. Such
helical peptides have been found to crystallize with the helix
axes either in an all-parallel motif or in an antiparallel motif.
Even peptides with the same sequence have either all-parallel
or antiparallel aggregation in different crystal forms (21, 22).
Similarly in [Leul]zervamicin, in crystals A and B (space
group P21), the nonpolar face of the helix associates in an
antiparallel fashion, while in crystals C and D (space group
P212121), the nonpolar face associates in a parallel fashion.
The inference can be drawn that the nonpolar face is also
fairly insensitive to the helix axis direction with respect to the
membrane.
DISCUSSION
[LeulJzervamicin is a bent helical molecule, 29 A long, with
all the polar side chains on the convex side and the nonpolar
side chains on the concave side. Alamethicin (3), also a bent
helix, has a much smaller degree of bending and has fewer
polar moieties on the convex face (Fig. 1). The helix in both
peptides is flexible as shown by different amounts of bending
in the three conformers in the same crystal of alamethicin and
the four conformers in four different polymorphs of [Leul]-
zervamicin. Although complex irregular water channels were
observed in the alamethicin crystals, the polar residues are
not directed toward the center of the channel as might be
expected for a membrane ion channel (3). In each of the four
crystal forms of [Leul]zervamicin, the polar faces of adjacent
peptide molecules form the boundary of a water channel.
The molecular recognition of the nonpolar side of
[Leu']zervamicin is not very specific. Either parallel or
antiparallel association takes place in the different crystal
forms. In contrast, the polar face is very specific in forming
an antiparallel association with an adjacent molecule and a
hydrogen bond between Hyp'0 and GIn", among others. The
Hypl0 Gln" hydrogen bond interrupts the water channel.
The remarkable observation is that the Gln" side chain has
to reverse its direction, in a swinging-arm fashion, to ap-
proach the Hyp'0 of an adjacent, antiparallel peptide. It may
be indicative of the gating mechanism in ion transport under
the application of a potential. The size of the water channel
near its interruption is restricted to one water molecule or one
cation. The implications from the crystal structure analyses
are that the water channel is not an open channel-i.e., that
there is no passive diffusion of cations. This point has been
emphasized further by soaking crystals in KCI solution for
various times at various concentrations. Short of the crystal
cracking and disintegrating, the soaking produced crystals
with somewhat different cell parameters, but with no K+
penetration.
Time-resolved fluorescence anisotropy measurements on
helical bilayer-spanning 21-residue peptides have shown that
the amplitude of fast fluctuations are largest at the helix ends
and decrease toward the center of the helix (23). The four
crystal structures show an expansion or constriction of the
mouth of the channel, 0(16) ... GIn3, that varies from 3.7 A
to >8.0 A. The cation may be trapped in the channel by
constriction of the mouth (24).
One of the interesting implications of the crystal structure
of [Leul]zervamicin is the role played by the mobility of the
long side chain of Gln residues: the demonstrated mobility of
Gln3 in controlling the size of the mouth of the water channel,
and the implied mobility of Gln" (by its unusual conforma-
tion) in probable participation in the gating mechanism. For
proteins, the role of Gln residues has been characterized as
relatively indifferent and has no extreme properties or violent
preferences (25). Perhaps one of the distinctive functions of
this residue is in the regulation of ion-transport peptides.
This research was supported in part by National Institutes of
Health Grant GM30902, in part by the Office of Naval Research, and
in part by a grant from the Department of Science and Technology,
India. S.A. was supported by a fellowship of the Council of Scientific
and Industrial Research, India.
1. Mueller, P. & Rudin, D. 0. (1968) Nature (London) 217,
713-719.
2. Nagaraj, R. & Balaram, P. (1981) Acc. Chem. Res. 14, 356-362.
3. Fox, R. 0. & Richards, F. M. (1982) Nature (London) 300,
325-330.
4. Mathew, M. K. & Balaram, P. (1983) Mol. Cell Biochem. 50,
47-64.
5. Hall, J. E., Vodyanoy, I., Balasubramanian, T. M. & Marshall,
G. R. (1984) Biophys. J. 45, 233-247.
6. Menestrina, G., Voges, K.-P., Jung, G. & Boheim, G. (1986) J.
Membr. Biol. 93, 111-132.
7. Argoudelis, A. D. & Johnson, L. E. (1974) J. Antibiot. 27,
274-282.
8. Rinehart, K. L., Jr., Gaudioso, L. A., Moore, M. L., Pandey,
R. C., Cook, J. C., Jr., Barber, M., Sedgwick, R. D., Bordoli,
R. S., Tyler, A. N. & Green, B. N. (1981) J. Am. Chem. Soc.
103, 6517-6520.
9. Mellor, I. R., Sansom, M. S. P., Krishna, K. & Balaram, P.
(1989) in Ion Transport, eds. Keeling, D. & Benham, C.
(Academic, New York), pp. 316-318.
10. Krishna, K., Sukumar, M. & Balaram, P. (1990) Pure Appl.
Chem. 62, 1417-1420.
11. Egert, E. & Sheldrick, G. M. (1985) Acta Crystallogr. Sect. A
41, 262-268.
12. Karle, I. L., Flippen-Anderson, J., Sukumar, M. & Balaram, P.
(1987) Proc. Nati. Acad. Sci. USA 84, 5087-5091.
13. Karle, J. (1968) Acta Crystallogr. Sect. B 24, 182-186.
14. Toniolo, C., Bonora, G. M., Bavoso, A., Benedetti, E., di
Blasio, B., Pavone, V. & Pedone, C. (1983) Biopolymers 22,
205-215.
15. Marshall, G. R., Hodgkin, E. E., Langs, D. A., Smith, G. D.,
Zabrocki, J. & Leplawy, M. T. (1990) Proc. Nati. Acad. Sci.
USA 87, 487-491.
16. Karle, I. L. & Balaram, P. (1990) Biochemistry 29, 6747-6756.
17. Schiffer, M. & Edmundson, A. B. (1967) Biophys. J. 7, 121-
135.
18. Kaiser, E. T. & Kezdy, F. J. (1984) Science 223, 249-255.
19. IUPAC-IUB Commission on Biochemical Nomenclature (1970)
Biochemistry 9, 3471-3479.
20. Stankovic, C. J., Heinemann, S. H. & Schreiber, S. L. (1990)
J. Am. Chem. Soc. 112, 3702-3704.
21. Karle, I. L., Flippen-Anderson, J. L., Sukumar, M. & Bal-
aram, P. (1990) Int. J. Pept. Protein Res. 35, 518-526.
22. Karle, I. L., Flippen-Anderson, J. L., Uma, K. & Balaram, P.
(1990) Biopolymers 29, 1835-1845.
23. Vogel, H., Nilsson, L., Rigler, R., Voges, K.-P. & Jung, G.
(1988) Proc. Nati. Acad. Sci. USA 85, 5067-5071.
24. Miller, C. (1989) Neuron 2, 1195-1205.
25. Richardson, J. S. & Richardson, D. C. (1990) in Prediction of
Protein Structure and the Principles ofProtein Conformation,
ed. Fasman, G. D. (Plenum, New York), pp. 1-98.
Biochemistry: Karle et al.
